2'-methyluridine | 1365634-47-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2'-methyluridine
• 英文别名: propan-2-yl (2S)-2-[[[(3aR,4R,6R,6aR)-4-(2,4-dioxopyrimidin-1-yl)-3a-methylspiro[6,6a-dihydro-4H-furo[3,4-d][1,3]dioxole-2,1'-cyclopentane]-6-yl]methoxy-phenoxyphosphinothioyl]amino]propanoate
• CAS: 1365634-47-4
• 化学式: C₂₇H₃₆N₃O₉PS
• 分子量: 609.637
• InChiKey: WAACIKFIZOGFAL-ZMCGFQSASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  41
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  166
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  2'-methyluridine 在 吡啶 、 甲酸 、 水 作用下， 反应 19.5h， 生成 2',3'-O-dipropionyl-2'-C-methyluridine 5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate
  参考文献：
  名称：

  SUBSTITUTED NUCLEOTIDE ANALOGS

  摘要：

  本文披露了磷酸硫代酯核苷类似物，合成磷酸硫代酯核苷类似物的方法，以及利用磷酸硫代酯核苷类似物治疗病毒感染、癌症和/或寄生虫病等疾病和/或症状的方法。

  公开号：

  US20120071434A1
• 作为产物：
  描述：

  2’-C-甲基尿苷 在 N-甲基咪唑 、 对甲苯磺酸 、 原甲酸三甲酯 作用下， 以 乙腈 为溶剂， 反应 2.0h， 生成 2'-methyluridine
  参考文献：
  名称：

  SUBSTITUTED NUCLEOTIDE ANALOGS

  摘要：

  本文披露了磷酸硫代酯核苷类似物，合成磷酸硫代酯核苷类似物的方法，以及利用磷酸硫代酯核苷类似物治疗病毒感染、癌症和/或寄生虫病等疾病和/或症状的方法。

  公开号：

  US20120071434A1

文献信息

• [EN] SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PRODRUG<br/>[FR] FORMES SOLIDES D'UN PROMÉDICAMENT NUCLÉOTIDIQUE THIOPHOSPHORAMIDATE
  申请人：VERTEX PHARMA

  公开号：WO2013142124A8

  公开（公告）日：2014-05-15
• Solid Forms of a Thiophosphoramidate Nucleotide Prodrug
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20130266538A1

  公开（公告）日：2013-10-10

  The present application relates to solid state forms, for example, crystalline forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.
• PHARMACEUTICAL COMPOSITIONS
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150065439A1

  公开（公告）日：2015-03-05

  Described herein are compositions that can include Compound 1 or Form J of Compound 1, or a pharmaceutically acceptable salt of the aforementioned compounds. Also, described herein is a method of treating a HCV infection in a subject that can include administering to the subject a composition that includes Compound 1 or Form J of Compound 1, or a pharmaceutically acceptable salt of the aforementioned compounds.
• SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PRODRUG
  申请人：Alios BioPharma, Inc.

  公开号：US20150175647A1

  公开（公告）日：2015-06-25

  The present application relates to solid state forms, for example, crystalline forms of 2′-C-methyluridine-5′-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.
• US8871737B2
  申请人：——

  公开号：US8871737B2

  公开（公告）日：2014-10-28